CHU de Nantes - Hôtel Dieu
CHU de Nantes - Hôtel Dieu
Nantes, France10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT02889523 | |
| TARGETed Therapy Drug MONITOring in DIGestive Oncology | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastrointestinal stromal tumor, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, rectal disorder | Recruiting | Not applicable | 2026-08-03 | NCT05443087 | |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-07-17 | NCT05429632 | |
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 3 | 2026-06-15 | NCT06006117 | |
| Study of Lacutamab in Peripheral T-cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04984837 | |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | diffuse large B-cell lymphoma | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04974216 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T) | Hematopathology Eligible or CAR-t Cell Treatment | Recruiting | Not stated | 2026-03-04 | NCT04328298 | |
| TOETVA Technique Compared With Anterior Cervical Thyroidectomy (AC) in Terms of Efficacy and Safety | Lobectomy; Thyroidectomy | Recruiting | Not applicable | 2026-01-16 | NCT07055191 | |
| Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | Recruiting | Not stated | 2026-01-14 | NCT04220970 |